Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma

The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Using tumor sampl...

Full description

Saved in:
Bibliographic Details
Published inJournal of pathology and translational medicine Vol. 46; no. 3; pp. 237 - 245
Main Authors Lee, Ji Won, Park, Jeong Hwan, Suh, Ja Hee, Nam, Kyung Han, Choe, Ji-Young, Jung, Hae Yoen, Chae, Ji Yoen, Moon, Kyung Chul
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society of Pathologists, Korean Society for Cytopathology 01.06.2012
The Korean Society of Pathologists and The Korean Society for Cytopathology
대한병리학회
Subjects
Cancer
Cell culture
Kinases
Original
Studies
병리학
Carcinoma, renal cell
Cyclooxygenase 2
Prognosis
Online AccessGet full text
ISSN1738-1843
2383-7837
2092-8920
2092-8920
2383-7845
DOI10.4132/KoreanJPathol.2012.46.3.237

Cover

Abstract The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
AbstractList Background: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX- 2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Methods: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)- 2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Results: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. Conclusions: This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC. [PUBLICATION ABSTRACT]
The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
Background: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Methods: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Results: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. Conclusions: This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC. KCI Citation Count: 0
The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.BACKGROUNDThe prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.METHODSUsing tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.RESULTSCancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.CONCLUSIONSThis study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
Author Lee, Ji Won
Moon, Kyung Chul
Suh, Ja Hee
Chae, Ji Yoen
Choe, Ji-Young
Jung, Hae Yoen
Nam, Kyung Han
Park, Jeong Hwan
AuthorAffiliation 3 Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
2 Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
1 Department of Pediatrics, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: 3 Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– name: 2 Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– name: 1 Department of Pediatrics, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Ji Won
  surname: Lee
  fullname: Lee, Ji Won
  organization: Department of Pediatrics, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Jeong Hwan
  surname: Park
  fullname: Park, Jeong Hwan
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Ja Hee
  surname: Suh
  fullname: Suh, Ja Hee
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Kyung Han
  surname: Nam
  fullname: Nam, Kyung Han
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Ji-Young
  surname: Choe
  fullname: Choe, Ji-Young
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Hae Yoen
  surname: Jung
  fullname: Jung, Hae Yoen
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Ji Yoen
  surname: Chae
  fullname: Chae, Ji Yoen
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Kyung Chul
  surname: Moon
  fullname: Moon, Kyung Chul
  organization: Department of Pathology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea., Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23110009$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001670414$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqNkk1P3DAQhi1EBQvlL1SWuHBJ8FfsRJWQVhGFbZGKKL1iGcdZDF57sbMV--9x2JYWTj2NZT_zzjue2QPbPngDwCFGJcOUHH8L0Sj_9VINd8GVBGFSMl7SklCxBSYENaSoG4K2wQQLWhe4ZnQX7KV0jxBnjKMdsEsoxgihZgJu2rV2ITyt58arZAoCT5-W0aRkg4fKd3A2JHgZw9yHNFgNf9i5t73VymsDrYetMyrC1jgHr7KC2xxbFbX1YaE-gg-9cskc_I774OeX0-v2vLj4fjZrpxeFrio-FLzSiCvGeyS06DDtDOlZrTRuKlMxwxipKB-vNe0QxeK210SI3I1uMFO9oPvgaKPrYy8ftJVB2Zc4D_IhyunV9UzWpKkpzejJBl2ubhem08YPUTm5jHah4vol8e2Lt3dZ5pekTDSC87-1ljE8rkwa5MImndtW3oRVkhgTJipck9HW4Tv0Pqxi_qZMIUpxIzAhmfr0r6NXK3-mlIHPG0DHkFI0_SuCkRx3Qr7ZCTnuhGRc0iwxmpi-y9Z2UEMecG7Puv_SeAaMxcNB
CitedBy_id crossref_primary_10_3389_fphar_2024_1365802
crossref_primary_10_7314_APJCP_2016_17_2_535
crossref_primary_10_1038_srep28932
crossref_primary_10_1007_s10911_015_9333_4
crossref_primary_10_1016_j_jep_2021_114740
crossref_primary_10_1111_vco_12264
crossref_primary_10_1007_s00405_018_5058_5
crossref_primary_10_1016_j_jep_2020_113547
crossref_primary_10_1016_j_canlet_2013_08_006
crossref_primary_10_1002_pbc_30110
crossref_primary_10_1097_CMR_0000000000000282
crossref_primary_10_1186_s12935_023_02967_x
crossref_primary_10_2217_fon_14_152
crossref_primary_10_1038_srep41371
crossref_primary_10_18632_oncotarget_21538
crossref_primary_10_1371_journal_pone_0082907
Cites_doi 10.1245/s10434-010-0985-4
10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
10.1007/s13277-010-0141-6
10.1016/j.eururo.2005.12.039
10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B
10.1002/cncr.21661
10.2174/138945011795677764
10.1007/978-1-4615-0193-0_20
10.1111/j.1365-2559.2004.01898.x
10.1016/j.urology.2004.07.023
10.1159/000288243
10.1093/jjco/hyp089
10.1136/jcp.2010.080713
10.3322/canjclin.57.1.43
10.1002/ijc.11646
10.1016/j.eururo.2007.03.035
10.3349/ymj.2005.46.1.133
10.1097/01.ju.0000143440.08760.3a
10.1016/j.cca.2010.12.026
10.1097/00000478-198210000-00007
ContentType Journal Article
Copyright Copyright Korean Society of Pathologists, Korean Society for Cytopathology Jun 2012
2012 The Korean Society of Pathologists/The Korean Society for Cytopathology 2012
Copyright_xml – notice: Copyright Korean Society of Pathologists, Korean Society for Cytopathology Jun 2012
– notice: 2012 The Korean Society of Pathologists/The Korean Society for Cytopathology 2012
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
BVBZV
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
ACYCR
DOI 10.4132/KoreanJPathol.2012.46.3.237
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
East & South Asia Database
ProQuest One Community College
ProQuest Central
ProQuest Central Student
ProQuest Research Library
ProQuest research library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
East & South Asia Database
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2092-8920
2383-7845
EndPage 245
ExternalDocumentID oai_kci_go_kr_ARTI_829833
PMC3479766
2734635841
23110009
10_4132_KoreanJPathol_2012_46_3_237
Genre Journal Article
Feature
GroupedDBID 5-W
5GY
8G5
8JR
9ZL
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
ADRAZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BENPR
BPHCQ
BVBZV
CITATION
DIK
DWQXO
EF.
ESX
GNUQQ
GUQSH
HYE
KQ8
M2O
M48
PGMZT
RNS
RPM
TUS
NPM
3V.
7XB
8FK
ACYCR
AFKRA
AZQEC
BCNDV
CCPQU
GROUPED_DOAJ
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PROAC
Q9U
7X8
5PM
IPNFZ
M~E
OK1
RIG
ID FETCH-LOGICAL-c556t-65c06a46f07c7d13de2f48ac195e54e44253613dec3d0317bfc277644c914af73
IEDL.DBID M48
ISSN 1738-1843
2383-7837
2092-8920
IngestDate Tue Nov 21 21:04:26 EST 2023
Thu Aug 21 13:29:13 EDT 2025
Thu Jul 10 22:03:20 EDT 2025
Mon Jun 30 06:31:19 EDT 2025
Thu Apr 03 07:00:41 EDT 2025
Tue Jul 01 00:30:30 EDT 2025
Thu Apr 24 23:01:19 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Carcinoma, renal cell
Cyclooxygenase 2
Prognosis
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c556t-65c06a46f07c7d13de2f48ac195e54e44253613dec3d0317bfc277644c914af73
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
G704-000333.2012.46.3.001
OpenAccessLink https://www.proquest.com/docview/1033197122?pq-origsite=%requestingapplication%
PMID 23110009
PQID 1033197122
PQPubID 1146335
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_829833
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3479766
proquest_miscellaneous_1124751827
proquest_journals_1033197122
pubmed_primary_23110009
crossref_primary_10_4132_KoreanJPathol_2012_46_3_237
crossref_citationtrail_10_4132_KoreanJPathol_2012_46_3_237
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20120601
PublicationDateYYYYMMDD 2012-06-01
PublicationDate_xml – month: 6
  year: 2012
  text: 20120601
  day: 1
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
– name: Seoul
PublicationTitle Journal of pathology and translational medicine
PublicationTitleAlternate Korean J Pathol
PublicationYear 2012
Publisher Korean Society of Pathologists, Korean Society for Cytopathology
The Korean Society of Pathologists and The Korean Society for Cytopathology
대한병리학회
Publisher_xml – name: Korean Society of Pathologists, Korean Society for Cytopathology
– name: The Korean Society of Pathologists and The Korean Society for Cytopathology
– name: 대한병리학회
References Ljungberg (10.4132/KoreanJPathol.2012.46.3.237_ref3) 2007; 51
Masferrer (10.4132/KoreanJPathol.2012.46.3.237_ref13) 2000; 60
Tuna (10.4132/KoreanJPathol.2012.46.3.237_ref25) 2004; 64
Soslow (10.4132/KoreanJPathol.2012.46.3.237_ref23) 2000; 89
Kovacs (10.4132/KoreanJPathol.2012.46.3.237_ref2) 1997; 183
Fosslien (10.4132/KoreanJPathol.2012.46.3.237_ref6) 2001; 31
Chen (10.4132/KoreanJPathol.2012.46.3.237_ref28) 2004; 172
Miyata (10.4132/KoreanJPathol.2012.46.3.237_ref17) 2003; 9
Witton (10.4132/KoreanJPathol.2012.46.3.237_ref9) 2004; 45
Herceg (10.4132/KoreanJPathol.2012.46.3.237_ref10) 2009; 29
Shinohara (10.4132/KoreanJPathol.2012.46.3.237_ref14) 2009; 39
Kim (10.4132/KoreanJPathol.2012.46.3.237_ref12) 2004; 12
Jemal (10.4132/KoreanJPathol.2012.46.3.237_ref1) 2007; 57
Rizzo (10.4132/KoreanJPathol.2012.46.3.237_ref4) 2011; 412
Rini (10.4132/KoreanJPathol.2012.46.3.237_ref24) 2006; 106
Ronkainen (10.4132/KoreanJPathol.2012.46.3.237_ref18) 2011; 32
Kankuri-Tammilehto (10.4132/KoreanJPathol.2012.46.3.237_ref19) 2010; 30
Kim (10.4132/KoreanJPathol.2012.46.3.237_ref11) 2010; 63
Cho (10.4132/KoreanJPathol.2012.46.3.237_ref20) 2005; 46
Edge (10.4132/KoreanJPathol.2012.46.3.237_ref21) 2010; 17
Sato (10.4132/KoreanJPathol.2012.46.3.237_ref30) 2010; 84
Chen (10.4132/KoreanJPathol.2012.46.3.237_ref29) 2004; 108
Hara (10.4132/KoreanJPathol.2012.46.3.237_ref8) 2002; 507
Khan (10.4132/KoreanJPathol.2012.46.3.237_ref16) 2011; 12
Fuhrman (10.4132/KoreanJPathol.2012.46.3.237_ref22) 1982; 6
Mungan (10.4132/KoreanJPathol.2012.46.3.237_ref27) 2006; 50
Yoshimura (10.4132/KoreanJPathol.2012.46.3.237_ref15) 2004; 13
Fosslien (10.4132/KoreanJPathol.2012.46.3.237_ref5) 2000; 30
Karim (10.4132/KoreanJPathol.2012.46.3.237_ref7) 2005; 25
Yoshimura (10.4132/KoreanJPathol.2012.46.3.237_ref26) 2004; 13
10728691 - Cancer Res. 2000 Mar 1;60(5):1306-11
9390023 - J Pathol. 1997 Oct;183(2):131-3
10678579 - Ann Clin Lab Sci. 2000 Jan;30(1):3-21
16369983 - Cancer. 2006 Feb 1;106(3):566-75
15138613 - Int J Mol Med. 2004 Jun;13(6):789-93
16080553 - Anticancer Res. 2005 Jul-Aug;25(4):2969-71
14712483 - Int J Cancer. 2004 Mar 1;108(6):825-32
19661295 - Anticancer Res. 2009 Aug;29(8):2913-7
20389170 - Urol Int. 2010;84(3):362-8
12738729 - Clin Cancer Res. 2003 May;9(5):1741-9
20683050 - Anticancer Res. 2010 Jul;30(7):3023-30
14719128 - Int J Mol Med. 2004 Feb;13(2):229-33
15538221 - J Urol. 2004 Dec;172(6 Pt 1):2153-7
21187081 - Clin Chim Acta. 2011 Apr 11;412(9-10):671-87
15744816 - Yonsei Med J. 2005 Feb 28;46(1):133-40
20180029 - Ann Surg Oncol. 2010 Jun;17(6):1471-4
12664575 - Adv Exp Med Biol. 2002;507:123-6
21161467 - Tumour Biol. 2011 Jun;32(3):481-7
16426736 - Eur Urol. 2006 Jul;50(1):92-7; discussion 97
21443470 - Curr Drug Targets. 2011 Jun;12(7):1082-93
15228443 - Histopathology. 2004 Jul;45(1):47-54
15254709 - Oncol Rep. 2004 Aug;12(2):403-9
15596182 - Urology. 2004 Dec;64(6):1116-20
11688844 - Ann Clin Lab Sci. 2001 Oct;31(4):325-48
19684042 - Jpn J Clin Oncol. 2009 Nov;39(11):720-6
20924037 - J Clin Pathol. 2010 Dec;63(12):1048-53
17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
11135226 - Cancer. 2000 Dec 15;89(12):2637-45
7180965 - Am J Surg Pathol. 1982 Oct;6(7):655-63
17408850 - Eur Urol. 2007 Jun;51(6):1502-10
References_xml – volume: 60
  start-page: 1306
  year: 2000
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref13
  publication-title: Cancer Res
– volume: 30
  start-page: 3
  year: 2000
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref5
  publication-title: Ann Clin Lab Sci
– volume: 17
  start-page: 1471
  year: 2010
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref21
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-010-0985-4
– volume: 183
  start-page: 131
  year: 1997
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref2
  publication-title: J Pathol
  doi: 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
– volume: 30
  start-page: 3023
  year: 2010
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref19
  publication-title: Anticancer Res
– volume: 13
  start-page: 229
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref26
  publication-title: Int J Mol Med
– volume: 32
  start-page: 481
  year: 2011
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref18
  publication-title: Tumour Biol
  doi: 10.1007/s13277-010-0141-6
– volume: 50
  start-page: 92
  year: 2006
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref27
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2005.12.039
– volume: 89
  start-page: 2637
  year: 2000
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref23
  publication-title: Cancer
  doi: 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B
– volume: 106
  start-page: 566
  year: 2006
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref24
  publication-title: Cancer
  doi: 10.1002/cncr.21661
– volume: 12
  start-page: 403
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref12
  publication-title: Oncol Rep
– volume: 12
  start-page: 1082
  year: 2011
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref16
  publication-title: Curr Drug Targets
  doi: 10.2174/138945011795677764
– volume: 31
  start-page: 325
  year: 2001
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref6
  publication-title: Ann Clin Lab Sci
– volume: 507
  start-page: 123
  year: 2002
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref8
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-0193-0_20
– volume: 45
  start-page: 47
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref9
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2004.01898.x
– volume: 64
  start-page: 1116
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref25
  publication-title: Urology
  doi: 10.1016/j.urology.2004.07.023
– volume: 84
  start-page: 362
  year: 2010
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref30
  publication-title: Urol Int
  doi: 10.1159/000288243
– volume: 25
  start-page: 2969
  year: 2005
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref7
  publication-title: Anticancer Res
– volume: 39
  start-page: 720
  year: 2009
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref14
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hyp089
– volume: 63
  start-page: 1048
  year: 2010
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref11
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2010.080713
– volume: 57
  start-page: 43
  year: 2007
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref1
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.57.1.43
– volume: 108
  start-page: 825
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref29
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11646
– volume: 51
  start-page: 1502
  year: 2007
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref3
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2007.03.035
– volume: 46
  start-page: 133
  year: 2005
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref20
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2005.46.1.133
– volume: 172
  start-page: 2153
  issue: 6 Pt 1
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref28
  publication-title: J Urol
  doi: 10.1097/01.ju.0000143440.08760.3a
– volume: 13
  start-page: 789
  year: 2004
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref15
  publication-title: Int J Mol Med
– volume: 9
  start-page: 1741
  year: 2003
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref17
  publication-title: Clin Cancer Res
– volume: 412
  start-page: 671
  year: 2011
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref4
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2010.12.026
– volume: 6
  start-page: 655
  year: 1982
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref22
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-198210000-00007
– volume: 29
  start-page: 2913
  year: 2009
  ident: 10.4132/KoreanJPathol.2012.46.3.237_ref10
  publication-title: Anticancer Res
– reference: 15744816 - Yonsei Med J. 2005 Feb 28;46(1):133-40
– reference: 16080553 - Anticancer Res. 2005 Jul-Aug;25(4):2969-71
– reference: 16426736 - Eur Urol. 2006 Jul;50(1):92-7; discussion 97
– reference: 21443470 - Curr Drug Targets. 2011 Jun;12(7):1082-93
– reference: 11688844 - Ann Clin Lab Sci. 2001 Oct;31(4):325-48
– reference: 17408850 - Eur Urol. 2007 Jun;51(6):1502-10
– reference: 10678579 - Ann Clin Lab Sci. 2000 Jan;30(1):3-21
– reference: 9390023 - J Pathol. 1997 Oct;183(2):131-3
– reference: 10728691 - Cancer Res. 2000 Mar 1;60(5):1306-11
– reference: 12738729 - Clin Cancer Res. 2003 May;9(5):1741-9
– reference: 21161467 - Tumour Biol. 2011 Jun;32(3):481-7
– reference: 20924037 - J Clin Pathol. 2010 Dec;63(12):1048-53
– reference: 20180029 - Ann Surg Oncol. 2010 Jun;17(6):1471-4
– reference: 12664575 - Adv Exp Med Biol. 2002;507:123-6
– reference: 15254709 - Oncol Rep. 2004 Aug;12(2):403-9
– reference: 17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
– reference: 19661295 - Anticancer Res. 2009 Aug;29(8):2913-7
– reference: 19684042 - Jpn J Clin Oncol. 2009 Nov;39(11):720-6
– reference: 7180965 - Am J Surg Pathol. 1982 Oct;6(7):655-63
– reference: 21187081 - Clin Chim Acta. 2011 Apr 11;412(9-10):671-87
– reference: 15228443 - Histopathology. 2004 Jul;45(1):47-54
– reference: 16369983 - Cancer. 2006 Feb 1;106(3):566-75
– reference: 15138613 - Int J Mol Med. 2004 Jun;13(6):789-93
– reference: 14719128 - Int J Mol Med. 2004 Feb;13(2):229-33
– reference: 20683050 - Anticancer Res. 2010 Jul;30(7):3023-30
– reference: 15596182 - Urology. 2004 Dec;64(6):1116-20
– reference: 20389170 - Urol Int. 2010;84(3):362-8
– reference: 14712483 - Int J Cancer. 2004 Mar 1;108(6):825-32
– reference: 11135226 - Cancer. 2000 Dec 15;89(12):2637-45
– reference: 15538221 - J Urol. 2004 Dec;172(6 Pt 1):2153-7
SSID ssj0064460
ssj0001453649
Score 1.9641052
Snippet The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical...
Background: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 237
SubjectTerms Cancer
Cell culture
Kinases
Original
Studies
병리학
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeJhBfhYGM4NWlsR074QVB1GkbYqoGk_aElTj2VtrZo-2k7b_nLnW7DSHEU6L4I875vuy7-EfIO8TXlkp51oCyY2CvJWt849mgaT3aNye6lP-vh2rvWB6c5Cdpw22e0ipXOrFT1G20uEcO0i2AW3TG-ceLXwxRozC6miA0NsgWqOAC-Hzr8_BwdHSzyyJzoTofGEyTYBqWY_fJW9AUoLv5-0kExyz8ROzfiGGIjPel6os-R1T0W2ZqI8z83zzQPxMpb1mm3YdkO7mU9NOSBx6Rey48Jj-qazuN8eoaGAQMFeN0eJVyXgOtQ0v3F3M6mkXMs4N29Nv4NGDWEDIBHQdaIZwErdx0So8cdt_dVog8FOJ5_YQc7w6_V3ssYSkwm-dqwVRuB6qWyg-01W0mWse9LGqblbnLpZMgukLhYytakHPdeMu1BmfJlpmsvRZPyWaIwT0nVGfeF84j0JiQHBEo8xzaWVsOWlgs6h75sCKdsemgccS7mBpYcCDdzZeO7gejju4G6W6kMsIA3XtErhtfLM_b-L9mb2COzMSODZ6XjdfTaCYzA6uCfVPwshCiR3ZWM2iSoM7NDVtBF-tiEDGMm9TBxUuoAz4QRqc4vObZcsLXYwP3GCMkZY_oO6ywroDDuVsSxmfdMd74D69W6sW_h_WSPMAvXWan7ZDNxezSvQI_aNG8Tsz-G9EvB3A
  priority: 102
  providerName: ProQuest
Title Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/23110009
https://www.proquest.com/docview/1033197122
https://www.proquest.com/docview/1124751827
https://pubmed.ncbi.nlm.nih.gov/PMC3479766
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001670414
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Pathology and Translational Medicine, 2012, 46(3), , pp.237-245
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED_tQ5p4QXzTMSojeE1IbMdueUEwbRpDnSZEpT1hJY4N1YrDsk5q_3vu0iRa0ZD2lCiOP-I7-z78yx3AO8qvLZXyUYGbXYTyWkaFL3yUFKUn-eZEA_mfnKmTqTy9yC62oAtP0E7g9Z2mHeWTmtbzeHm1-ogLHvXXGLdg_v5rhfpVOD3PyZFIaC0eSxWLmAu9DbsoohRZZRPZHy-gDqCSPXh7jwYoWLCgsGqEWLwlubZD7e9SSv_FVt4SVseP4GGrZbJPa7Z4DFsuPIG9SXuO_hR-HK7svKqWK2QfFGMRZ27ZImIDy0PJZotrRtCtUFEcZ0YoD8IUEYuwWWCWkk0wcvqz2lFPza2lvESh-p0_g-nx0ffDk6jNtBDZLFOLSGU2UblUPtFWl6koHfdylNt0nLlMOokLWyh6bEWJu4AuvOVa4zTacSpzr8Vz2AlVcC-B6dT7kfOUhkxITvkpswzrWTtOSjQl9QA-dLNobBuGnLJhzA2aI0QNs0ENQ9QwUhlhkBoDkH3lP-toHPer9gbJZS7tzFA0bbr-rMxlbdBm-GJGfDwSYgAHHTFNx4XYtsAtSqecYxN9MS5AmtU8uOoG30ENic6uOHbzYk37fmwd6wxAb3BF_wINZ7MkzH41Qb7pD1-t1P5_23wFD-gj17C1A9hZ1DfuNSpIi2IIu5-Pzs6_DRsHw7Bh_WHjx_oLTVQSIw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELa2TgJeEIhfHQOMgMeUxnbsBgkhKJ3adauqsUl7mkkce3Qtzmg7sf5T_I3cJWm3IYR42VOrJue458--u9zZHyGvkV9bSOmCFBa7AOy1CFKXuqCZZg7tm-VFyf_eQHYPxc5RdLRGfi33wmBZ5XJNLBbqLDf4jhxmNwe0qJCxD2c_AmSNwuzqkkKjhEXfLn5CyDZ73_sM4_uGse3OQbsbVKwCgYkiOQ9kZJoyEdI1lVFZyDPLnGglJowjGwkrAMRc4s-GZ4B4lTrDlAK3wcShSJzi0O462RC4o7VGNj51BsP9y7c6AoQLnxtMIQ8UhH-3yCtYmcBWsLfjHBxBf4pcwzmmPULWELLBGwxZ2K-YxXU_dX_zeP8s3LxiCbfvkbuVC0s_lpi7T9asf0CO2wszyfOLBQASDGPAaOeiqrH1NPEZ7c1ndDjNsa4P5OiX0YnHKiUEHR152kb6Ctq2kwndt9h88bWNTEc-_548JIc3ouVHpOZzb58QqkLnWtYhsRkXDBkvowjkjImbGQSnqk7eLVWnTXWwOfJrTDQEOKh33S_0vjMs9K5R71pIzTXovU7ESvisPN_j_8RewhjpsRlpPJ8bP09yPZ5qiEJ6usXiFud1srUcQV0tDDN9CWNoYnUZpjTmaRJv83O4B3wuzIYxeMzjcsBXfQN3HDMycZ2oa1BY3YDduX7Fj74Vx4bjnmEl5ea_u_WC3O4e7O3q3d6g_5TcwX9dVsZtkdp8em6fgQ82T59XwKfk603Ptd8NNENn
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLa2Tpp44SJuhQFGwGO61nbsFAkh1q1aV5gqYNO0B0zi2KO0OKMXwfhp_BX-DOfk0l2EEC974KlVk-PY6edzyTk5HyFPkV9bSOmCBJRdAPZaBIlLXNBMUof2zfK85P_NrtzeEzsH4cES-Vm9C4NllZVOzBV1mhl8Rg67mwNaVIuxdVeWRQw2uy-PvwbIIIWZ1opOo4BI3558g_Bt-qK3Cf_1M8a6W-8720HJMBCYMJSzQIamKWMhXVMZlbZ4apkTUWxa7dCGwgoANJf4s-EpoF8lzjClwIUw7ZaIneIw7jJZiWQUshpZ2djfONw_fcIjQDj3v8Es8kBBKLhKnoCWArvB1kcZOIX-M_IOZ5gCabGGkA3eYMjIfsZELvuJ-5P3e7GI84xV7F4jv6r7WRTDjBrzWdIwPy60mvw_b_h1crV01umrYnfdIEvW3yQfOidmnMF6YeuBCxAwuvW9rCb2NPYp7c2mdDDJsIIR5Oi74ZHHeizcXnToaQeJOmjHjsf0rcXh868d5HTy2Zf4Ftm7lCXdJjWfeXuXUNVyLrIOKdy4YMjtGYYgZ0y7mUIYrurkeQUMbcoW7sgkMtYQyiGqdD9H1c4gR5VGVGkhNdeAqjoRC-HjopPJv4k9BgTqkRlq7ESOn0eZHk00xFs9HbF2xHmdrFUQ0qUKnOpT_MAQi8OgvDAjFXubzeEc8C4x78fgMncKOC_mBoEH5p7adaLOAX1xAk7n_BE__JQ3SMe3o5WU9_4-rUdkFQCtX_d2-_fJFVx0UQK4Rmqzydw-AGdzljwsdzUlHy8b178BNeiOuQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cyclooxygenase-2+expression+and+its+prognostic+significance+in+clear+cell+renal+cell+carcinoma&rft.jtitle=The+Korean+journal+of+pathology&rft.au=Lee%2C+Ji+Won&rft.au=Park%2C+Jeong+Hwan&rft.au=Suh%2C+Ja+Hee&rft.au=Nam%2C+Kyung+Han&rft.date=2012-06-01&rft.eissn=2092-8920&rft.volume=46&rft.issue=3&rft.spage=237&rft_id=info:doi/10.4132%2FKoreanJPathol.2012.46.3.237&rft_id=info%3Apmid%2F23110009&rft.externalDocID=23110009
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-1843&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-1843&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-1843&client=summon